CGTN: What Are Generations of Chinese Communists Striving For?
27.2.2021 18:36:00 EET | Business Wire | Press release
The Communist Party of China (CPC), the ruling party of the world's most populous nation and the second largest economy, is turning 100 this year. What has been motivating the CPC to fight against one challenge after another over the past century?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210227005021/en/
"The original aspiration and the mission of Chinese Communists is to seek happiness for the Chinese people and rejuvenation for the Chinese nation," General Secretary Xi Jinping of the CPC Central Committee said in his report to the 19th CPC National Congress in October 2017.
"This founding aspiration, this mission, is what inspires the Chinese Communists to advance," Xi said.
Self-discipline, selflessness
In March 2018, Xi, also the Chinese president, further explained the cause pursued by the CPC with a quote from an ancient poem: "A virtuous person is as sharp-sighted as a clear mirror hanging high, a selfless person is just like a lit candle giving all of its light to others."
He made the quotation at a symposium to commemorate the 120th birthday of late Premier Zhou Enlai (1898-1976), who joined the CPC in 1921, the year when the Party was founded.
"The lofty character of comrade Zhou Enlai, who selflessly pursued a just cause for the common good throughout his life, vividly reflects the traditional virtue of the Chinese nation and good moral qualities of the Chinese Communists, and will forever earn the respect of future generations," said Xi.
The comments "not only aimed to remember the noble character of Zhou who was self-disciplined, upright, honest and selfless, but also to encourage today's Communists to stay true to their original aspirations of the Party and shoulder their responsibilities," said Meng Man, a history professor at Minzu University of China.
New challenges, same aspiration
The number of the CPC members has exceeded 90 million, and China has become a much stronger nation than 100 years ago and the early decades of the People's Republic of China, but the aspiration of the Chinese Communists remains unchanged.
"To meet the people's desire for a happy life is our mission," Xi said when meeting the press after being elected as general secretary of the CPC Central Committee in November 2012.
Three years later, the communique of the fifth plenary session of the 18th CPC Central Committee underscored a people-centered development philosophy, stressing that China's development must be for the people and by the people, and its fruits shared among the people.
The notion was highlighted again in the CPC Central Committee's proposals for formulating the 14th Five-Year Plan (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035, which called for efforts to promote common prosperity for everyone.
China, in recent years, has been striving to build a moderately prosperous society in all respects and pursuing more balanced development. The CPC members have played leading roles in a nationwide poverty alleviation campaign to make sure nobody is left behind.
Over the past eight years, more than three million public sector officials were sent from cities and towns to villages to fight against poverty on the front lines and over 1,800 people died during the fight, Xi said on Thursday after announcing the country's "complete victory" in eradicating absolute poverty.
Putting people's life and health first, China has taken strict measures to battle the COVID-19 pandemic and effectively contained the virus, thanks to people from all walks of life for their efforts and sacrifices, particularly the CPC members.
More than 39 million CPC members fought the virus at the front line, and more than 13 million volunteered their services. Nearly 400 CPC members have defended others' lives and safety at the cost of their own.
When many parts of the country grappled with severe floods last summer, the Organization Department of the CPC Central Committee issued a circular to call on primary-level CPC organizations and members to fully play their role in flood control and relief work, urging them to ensure the safety of people's lives and property.
As China embarks on a new journey to fully build a modern socialist country, today's Chinese Communists – putting the people's and the nation's interests above those of themselves – are gearing up to take on their responsibilities as the older generations did.
Original article: https://news.cgtn.com/news/2021-02-27/What-are-generations-of-Chinese-Communists-striving-for--YdM2IOWzO8/index.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210227005021/en/
Contact information
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
